SeroSelectTB participant enrolment commenced at two of the clinical sites in Cape Town on September 21st, 2021. Obtaining informed consent, data capture, specimen collection and SeroSelectTB testing went very well. CLIME has launched four new field studies during the last few months and this experience contributed to the successful SeroSelectTB start-up. The team anticipates that recruitment will be easy, and that minor improvements and modifications will make patient enrolment and data collection faster and better.
Congratulations to the team at CLIME!